Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A stabilized oral formulation of the BPC-157 pentadecapeptide sequence designed for gastrointestinal applications. Unlike standard BPC-157 which is typically injected, this formulation uses stabilization techniques to survive gastric acid degradation. Primarily studied for gut healing, ulcer protection, and inflammatory bowel conditions.
A synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in tissue repair and regeneration. Widely used in the biohacking community for injury recovery.
Same core mechanism as BPC-157 — upregulates growth factor expression (VEGF, EGF), promotes angiogenesis, and modulates the nitric oxide system. The oral formulation targets the GI tract directly, providing local healing effects on the gastric and intestinal mucosa before systemic absorption.
Promotes cell migration, blood vessel formation, and reduces inflammation. Upregulates actin, a cell-building protein critical for healing and cell migration to injury sites.
- Gut healing and repair
- Gastric ulcer protection
- Inflammatory bowel support
- Leaky gut syndrome (investigational)
- NSAID-induced GI damage protection
- Muscle and tendon repair
- Wound healing
- Reducing inflammation
- Hair regrowth (emerging research)
- Cardiac tissue repair
- Limited human clinical data
- GI discomfort possible
- Uncertain bioavailability compared to injectable
- Quality varies significantly between suppliers
- Not FDA-approved for any indication
- Limited human clinical data
- Potential tumor growth concerns (theoretical)
- Injection site reactions
- Headaches reported anecdotally
Shares regulatory status with BPC-157. Removed from Category 2 on April 22, 2026. Awaiting PCAC review at the July 23, 2026 meeting. The oral formulation is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.
PCAC: 2026-07-23
On April 15, 2026, the FDA announced TB-500 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 to determine eligibility for the 503A bulk drug substances list. Compounding pharmacies should exercise caution until PCAC takes action.
PCAC: July 23, 2026
- Thymosin β4 promotes dermal healing
2007 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.